Adverse ruling by ED Va on Celebrex patent creates problems for Pfizer

The invalidation of a method of use patent could cost Pfizer $1 billion in revenues this year and $2 billion next year.

See

Pfizer says U.S. court invalidates Celebrex patent; generics loom

 
ABC News stated

Trading of Pfizer shares on the New York Stock Exchange was briefly halted before the announcement. Shares closed at $31.98, down 44 cents, or 1.4 percent, but still near Pfizer's 52-week high. In after-hours trading, shares fell another 7 cents.

The case involves a "reissue patent" that prevented U.S. sales of generic versions until Dec. 2, 2015. Last March, the U.S. Patent & Trademark Office granted Pfizer the "reissue patent," which corrected what Pfizer called technical deficiencies in the original patent covering the diseases treated by the drug's active ingredient, celecoxib. Those include acute and menstrual pain, rheumatoid and osteoarthritis, and a painful spinal joint disorder called ankylosing spondylitis.

See also

Pfizer to appeal invalidated Celebrex patent